Source: MarketScreener

XBiotech: XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

( Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 -- XBiotech Inc. enrolled the first patient in a randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ....

Read full article »
Annual Revenue
John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating


Read more